폐경후 여성에서 여성호르몬과 알렌드로네이트 치료약제에 따른 골밀도와 골대사 표지물질의 변화

Abstract

The aim of this study was to investigate the effect of different classes of drugs, which are currently available for the treatment of osteoporosis. Forty nine postmenopausal women with osteoporosis participated in this study. Subjects were divided into IV groups: Group I was treated with activated vitamin D, Group II with estrogen, Group III with alendronate, and Group IV with estrogen and alendronate. Treatment duration was one year. The levels of serum calcium, phosphorous and alkaline phosphate (ALP) and urine deoxypyridinoline(DPD), osteocalcin and bone mineral densities (BMD) were determined before and after the treatment. The total serum ALP and osteocalcin were significantly decreased, and BMD was significantly increased in Group IV. However, significant difference in the markers to indicate bone metabolism was not found among Group I, II and III. The present study showed the combination therapy of alendronate and estrogen to be the most effective in improving BMD and tone chemical marker.